文献速递眼底病与葡萄膜炎

靶向Na/K-ATPase应激信号调控促进缺血性视网膜病变小鼠模型生理性血管再通

Stress Signal Regulation by Na/K-ATPase As a New Approach to Promote Physiological Revascularization in a Mouse Model of Ischemic Retinopathy.
PubMed 文献 · Invest Ophthalmol Vis Sci · 2020-01-01

本研究在小鼠氧诱导视网膜病变(OIR)模型中评估了pNaKtide(一种阻断α1 Na/K-ATPase/Src结合的细胞穿透肽)的作用。结果显示pNaKtide抑制病理性ROS信号并恢复HIF-1α/VEGF正常表达,与抗VEGF药物不同,pNaKtide在抑制新生血管和炎症的同时促进了视网膜血管再通。靶向α1 NKA是开发既抑制新生血管又促进生理性血管再通的新型治疗策略。

要点

  • pNaKtide阻断α1 NKA/Src/ROS放大环路,减少病理性ROS信号。
  • pNaKtide恢复HIF-1α/VEGF正常表达,抑制新生血管和炎症。
  • 与抗VEGF药物不同,pNaKtide促进视网膜生理性血管再通。

核心结论

  • 靶向α1 NKA/Src/ROS放大环路可同时抑制新生血管和促进生理性血管再通,是缺血性眼病的新型治疗策略。

研究设计与样本

  • 体外使用人视网膜微血管内皮细胞(HRMECs)和视网膜色素上皮细胞(ARPE-19)评估pNaKtide对活力、增殖和血管生成的影响及视网膜毒性和分布。
  • 体内采用小鼠氧诱导视网膜病变(OIR)模型,生化评估NKA/Src在ROS应激信号中的作用及pNaKtide疗效。

主要发现

  • α1 NKA在小鼠OIR视网膜ROS应激和Nrf2通路调控中起关键作用。
  • pNaKtide抑制α1 NKA/Src,减少病理性ROS信号并恢复HIF-1α/VEGF正常表达。
  • pNaKtide促进视网膜血管再通,同时抑制新生血管和炎症,与抗VEGF药物不同。

临床怎么用

  • pNaKtide代表一种既抑制新生血管又促进生理性血管再通的潜在治疗策略,有待进一步临床转化验证。

局限性

  • 研究仅基于细胞和小鼠OIR模型,尚未在人体中验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The identification of target pathways to block excessive angiogenesis while simultaneously restoring physiological vasculature is an unmet goal in the therapeutic management of ischemic retinopathies. pNaKtide, a cell-permeable peptide that we have designed by mapping the site of α1 Na/K-ATPase (NKA)/Src binding, blocks the formation of α1 NKA/Src/reactive oxygen species (ROS) amplification loops and restores physiological ROS signaling in a number of oxidative disease models. The aim of this study was to evaluate the importance of the NKA/Src/ROS amplification loop and the effect of pNaKtide in experimental ischemic retinopathy. METHODS: Human retinal microvascular endothelial cells (HRMECs) and retinal pigment epithelium (ARPE-19) cells were used to evaluate the effect of pNaKtide on viability, proliferation, and angiogenesis. Retinal toxicity and distribution were assessed in those cells and in the mouse. Subsequently, the role and molecular mechanism of NKA/Src in ROS stress signaling were evaluated biochemically in the retinas of mice exposed to the well-established protocol of oxygen-induced retinopathy (OIR). Finally, pNaKtide efficacy was assessed in this model. RESULTS: The results suggest a key role of α1 NKA in the regulation of ROS stress and the Nrf2 pathway in mouse OIR retinas. Inhibition of α1 NKA/Src by pNaKtide reduced pathologic ROS signaling and restored normal expression of hypoxia-inducible factor 1-α/vascular endothelial growth factor (VEGF). Unlike anti-VEGF agents, pNaKtide did promote retinal revascularization while inhibiting neovascularization and inflammation. CONCLUSIONS: Targeting α1 NKA represents a novel strategy to develop therapeutics that not only inhibit neovascularization but also promote physiological revascularization in ischemic eye diseases.

来源:Invest Ophthalmol Vis Sci,查看原文。版权归原作者所有。

引用

  1. Wang J, Wang X, Gao Y, et al. Stress Signal Regulation by Na/K-ATPase As a New Approach to Promote Physiological Revascularization in a Mouse Model of Ischemic Retinopathy. Invest Ophthalmol Vis Sci. 2020. PMID: 33275652. doi:10.1167/iovs.61.14.9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。